Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes Daniel J. Corsi, PhD; LauraWalsh, MSc; DeborahWeiss, PhD; Helen Hsu, MD; Darine El-Chaar, MD; Steven Hawken, PhD; Deshayne B. Fell, PhD; MarkWalker,MD JAMA, Published online June 18, 2019. doi:10.1001/jama.2019.8734 Key Points Question Is there an association between prenatal cannabis exposure and maternal, perinatal, and neonatal outcomes? Findings In this retrospective cohort study that included 661 617 pregnancies and 9427 reported cannabis users, the rate of preterm birth among reported cannabis users was 12% vs 6% in nonusers, a statistically significant difference. Meaning Reported cannabis use in pregnancy was associated with significant increases in the rate of preterm [...]
Lire la suiteDream over life : Psychedelic terphenyl derivative induce hallucination via cannabinoid receptor 1 F.A. Fauzi, M.S. Goh, S.A.T.T. Johari, F. Hashim, M.F.N. Hassim The International Fundamentum Sciences Symposium 2018 IOP Publishing IOP Conf. Series: Materials Science and Engineering 440 (2018) 012045 doi:10.1088/1757-899X/440/1/012045 Abstract. For ages, natural psychedelic resources have been used by ancient tribes for religious inspiration. In modern medicine, these compounds were prescribed to relieve severe distress and depression on cancer patients. Despite medical benefit, abuse of these compounds have become prevalent in our modern society. These compounds usually interacted withcannabinoid receptor 1 (CNR1) on neuron cell causing hallucination, and on other cell-types. In this [...]
Lire la suiteexcellent article de Jean-Yves Nau, avec deux réponses "pertinentes" du Pr Nicolas Authier et du Dr William Lowenstein Cannabis thérapeutique : l’activisme injustifiable de l’Académie nationale de pharmacie 18 juin 2019 jeanyvesnau addictions, Déontologie, Douleur, Médecine, médicament, Pharmacie, Polémique, Politique, Pouvoir, Risques (réduction des), santé publique, Toxicomanies Étiquettes : European Respiratory Journal, The Conversation, The Lancet https://jeanyvesnau.com/2019/06/18/cannabis-therapeutique-lactivisme-injustifiable-de-lacademie-nationale-de-pharmacie/ Bonjour Pour un peu on se gausserait. Sur le mode « l’Académie abuse la galerie ». Les faits : un communiqué de presse daté du 17 juin de l’Académie nationale de pharmacie : « Cannabis ‘’thérapeutique’’ : une appellation abusive et dangereuse ». Cette institution entend aujourd’hui « mettre en garde [...]
Lire la suiteModern History of Medical Cannabis : From Widespread Use to Prohibitionism and Back Simona Pisanti and Maurizio Bifulco Trends in Pharmacological Sciences, Cell Press, 2017, 38, 3, 195-198. doi: 10.1016/j.tips.2016.12.002. Over the history of pharmacology there are numerous examples of drugs being widely distributed, almost ‘trendy’, prescribed by physicians in a certain period as a sort of panacea, and then neglected, forgotten, or even forbidden as they become considered dangerous in the light of clinical observations. One of these drugs is Cannabis, which was very popular in the 19th century until disappearing from the official Pharmacopoeia at the beginning of the 20th century and [...]
Lire la suiteIntroduction to Recent Advances in Cannabinoid Research Robert B. Laprairie and Will Costain © 2016 The Author(s). Licensee InTechOpen. This chapter is distributed under the terms of the Creative Commons; Attribution License (http://creativecommons.org/licenses/by/3.0), Abstract On October 17, 2018, Canada became the first G20 nation to legalize the use of Cannabis sativa for both medicinal and recreational purposes. This change in legislation and end of prohibition are indicative of a larger global movement to understand Cannabis—and the bioactive chemicals present within Cannabis known as the cannabinoids—for its potential biomedical uses, harms, and economic values. Currently, interest in Cannabis and cannabinoid research is surging as the many [...]
Lire la suiteCannabis thérapeutique : au seuil de l’expérimentation Interview du Pr Nicolas Authier, chef du service de pharmacologie médicale, CHU de Clermont-Ferrand, président du Comité scientifique spécialisé temporaire (CSST) sur le cannabis thérapeutique JIM.fr, 16 juin 2019 cliquer sur "regardez sur Vimeo" ou : https://www.jim.fr/medecin/videos/e-docs/cannabis_therapeutique_au_seuil_de_lexperimentation_178085/document_jim_tube.phtml Chapitres Quelle différence existe-t-il entre cannabis thérapeutique et cannabis récréatif ? - 00:05 Quelle est la situation actuelle du cannabis thérapeutique en France ? - 00:54 Où en sont les travaux du CSST que vous présidez ? - 03:10 Quelles seront les indications du cannabis thérapeutiques pendant l’expérimentation ? 05:16 Quel est l’intérêt du cannabis thérapeutique [...]
Lire la suiteShould Physicians Recommend Replacing Opioids With Cannabis? Keith Humphreys PhD, Richard Saitz, MD, MPH JAMA, 2019, 321, 7, 639-640. doi : 10.1001/jama.2019.0077 https://jamanetwork.com/journals/jama/fullarticle/2723649 Recent state regulations (eg, in New York, Illinois) allow medical cannabis as a substitute for opioids for chronic pain and for addiction. Yet the evidence regarding safety, efficacy, and comparative effectiveness is at best equivocal for the former recommendation and strongly suggests the latter—substituting cannabis for opioid addiction treatments is potentially harmful. Neither recommendation meets the standards of rigor desirable for medical treatment decisions. Résumé : States that permit medical marijuana as an alternative to opioids for chronic pain and for addiction [...]
Lire la suiteThe Need for Federal Regulation of Marijuana Marketing John W. Ayers, PhD, Theodore Caputi, Eric C. Leas, PhD,MPH JAMA, June 11, 2019 Volume 321, Number 22 doi:10.1001/jama.2019.4432 A national for-profit marijuana industry is expanding substantially in the United States. Thirty-three states have legalized medical marijuana, 10 of which (where 1 in 4 individuals reside) have also legalized recreational marijuana. Sales of marijuana are projected to increase from $8.5 billion to $75 billion by 2030, rivaling current tobacco sales ($125 billion).1 The initial marijuana marketplace was limited to a few states, but emerging brands have developed sophisticated national marketing campaigns that could potentially have an [...]
Lire la suiteCSSS-N Commissions de la sécurité sociale et de la santé publique Secrétariat CH-3003 Berne www.parlament.ch sgk.csss@parl.admin.ch Vendredi, 03 mai 2019 15h50 Communiqué de presse Essais pilotes avec du cannabis: premier obstacle franchi La Commission de la sécurité sociale et de la santé publique du Conseil national est entrée en matière sur le projet prévoyant la création d’un article relatif aux projets pilotes dans la loi sur les stupéfiants. Elle souhaite permettre la réalisation d’études scientifiques sur la remise contrôlée de cannabis en vue d’une consommation récréative. Par 12 voix contre 9 et 2 abstentions, la Commission de la sécurité sociale et de la santé publique [...]
Lire la suiteHepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model Laura E. Ewing, Charles M. Skinner, Charles M. Quick, Stefanie Kennon-McGill, Mitchell R. McGill, Larry A. Walker, Mahmoud A. ElSohly, Bill J. Gurley and Igor Koturbash Molecules, 2019, 24, 1694 doi : 10.3390/molecules24091694 Abstract : The goal of this study was to investigate Cannabidiol (CBD) hepatotoxicity in 8-week-old male B6C3F1 mice. Animals were gavaged with either 0, 246, 738, or 2460 mg/kg of CBD (acute toxicity, 24 h) or with daily doses of 0, 61.5, 184.5, or 615 mg/kg for 10 days (sub-acute toxicity). These doses were the allometrically scaled mouse equivalent doses (MED) [...]
Lire la suite